AstraZeneca: FDA approves new lung cancer drug
(CercleFinance.com) - US regulators have approved AstraZeneca's Tagrisso for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC), the drugmaker said on Thursday.
In a phase III trial, Tagrisso delivered "unprecedented" median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care, the company said.
Its shares are almost flat at 4,959 pence in early morning trading in London today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In a phase III trial, Tagrisso delivered "unprecedented" median progression-free survival of 18.9 months versus 10.2 months compared with current standard of care, the company said.
Its shares are almost flat at 4,959 pence in early morning trading in London today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.